ESBL-producing multidrug-resistant Providencia stuartii infections in a university hospital

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 2, 2004, Pages 277-282

  Tumbarello, Mario ^a   Citton, Rita ^a   Spanu, Teresa ^a   Sanguinetti, Maurizio ^a   Romano, Lucio ^a   Fadda, Giovanni ^a   Cauda, Roberto ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Antibiotic resistance; Enterobacteriaceae; ESBLs; Nosocomial outbreak; P. stuartii

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZTREONAM; BACTERIAL DNA; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFALOTIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULBACTAM;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CONTROLLED STUDY; CROSS RESISTANCE; DNA SEQUENCE; DRUG SENSITIVITY; EPIDEMIOLOGICAL DATA; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; ITALY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; POLYMERASE CHAIN REACTION; PROVIDENCIA STUARTII; RISK FACTOR; STRAIN DIFFERENCE; UNIVERSITY HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; BETA-LACTAMASES; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; ITALY; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROVIDENCIA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 1242285175     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh047     Document Type: Article

References (40)

1. Medeiros, A. A. (1997). Evolution and dissemination of β-lactamases accelerated by generation of β-lactam antibiotics. Clinical Infectious Diseases 24, Suppl. 1, S19-S45.
2. Bradford, P. A. (2001). Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clinical Microbiology Reviews 14, 933-51.
3. Livermore, D. M. (1995). β-Lactamases in laboratory and clinical resistance. Clinical Microbiology Reviews 8, 557-84.
4. Knothe, H., Shah, P., Krcmery, V. et al. (1983). Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 11, 315-7.
5. Coudron, P. E., Moland, E. S. & Sanders, C. C. (1997). Occurrence and detection of extended-spectrum β-lactamases in members of the family Enterobacteriaceae at a veterans medical center: seek and you may find. Journal of Clinical Microbiology 35, 2593-7.
6. Rahal, J. J., Urban, C. & Segal-Maurer, S. (2002). Nosocomial antibiotic resistance in multiple Gram-negative species: experience at one hospital with squeezing the resistance balloon at multiple sites. Clinical Infectious Diseases 34, 499-503.
7. Bisson, G., Fisherman, N. O., Patel, J. B. et al. (2002). Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species: risk factors for colonization and impact of antimicrobial formulary interventions on colonization prevalence. Infection Control and Hospital Epidemiology 23, 254-60.
8. D'Agata, E., Venkataraman, L., DeGirolami, P. et al. (1998). The molecular and clinical epidemiology of Enterobacteriaceae producing extended-spectrum β-lactamase in a tertiary care hospital. Journal of Infection 36, 279-85.
9. Navon-Venezia, S., Hammer-Munz, O., Schwartz, D. et al. (2003). Occurrence and phenotypic characteristics of extended-spectrum β-lactamases among members of the family Enterobacteriaceae at the Tel-Aviv Medical Center (Israel) and evaluation of diagnostic tests. Journal of Clinical Microbiology 41, 155-8.
10. Jacoby, G. A. (1997). Extended-spectrum β-lactamases and other enzymes providing resistance to oxyimino-β-lactams. Infectious Disease Clinics of North America 11, 875-87.
11. Brun-Buisson, C., Legrand, P., Philippon, A. et al. (1987). Transferable enzymatic resistance to third generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet ii, 302-6.
12. O'Hara, C. M., Brenner, F., Miller, M. (2000). Classification, identification, and clinical significance of Proteus, Providencia, and Morganella. Clinical Microbiology Reviews 13, 534-46.
13. National Committee for Clinical Laboratory Standards. (2002). Performance Standards for Antimicrobial Susceptibility Testing: Twelfth Informational Supplement M100-S12. NCCLS, Wayne, PA, USA.
14. Franceschini, N., Perilli, M., Segatore, B. et al. (1998). Ceftazidime and aztreonam resistance in Providencia stuartii: characterization of a natural TEM-derived extended-spectrum β-lactamase, TEM-60. Antimicrobial Agents and Chemotherapy 42, 1459-62.
15. Garner, J. S., Jarvis, W. R., Emori, T. G. et al. (1988). CDC definitions for nosocomial infections. American Journal of Infection Control 16, 128-39.
16. Knaus, W. A., Wagner, D. P., Draper, E. A. et al. (1991). The APACHE III prognostic system: risk prediction of hospital mortality for critically ill hospitalized adults. Chest 100, 1619-36.
17. Spanu, T., Luzzaro, F., Perilli, M. et al. (2002). Occurrence of extended-spectrum β-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to β-lactams and other antimicrobial drugs. Antimicrobial Agents and Chemotherapy 46, 196-202.
18. Sanguinetti, M., Posteraro, B., Spanu, T. et al. (2003). Characterization of clinical isolates of Enterobacteriaceae from Italy by the BD Phoenix extended-spectrum β-lactamase detection method. Journal of Clinical Microbiology 41, 1463-8.
19. Snelling, A. M., Gerner-Smidt, P., Hawkey, P. et al. (1996). Validation of use of whole-cell repetitive extragenic palindromic sequence-based PCR (REP-PCR) for typing strains belonging to the Acinetobacter calcoaceticus-Acinetobacter baumannii complex and application of the method to the investigation of a hospital outbreak. Journal of Clinical Microbiology 34, 1193-1202.
20. De Champs, C., Sirot, D., Chanal, C. et al. (2000). A 1998 survey of extended-spectrum β-lactamases in Enterobacteriaceae in France. Antimicrobial Agents and Chemotherapy 44, 3177-9.
21. Perilli, M., Dell'Amico, E., Segatore, B. et al. (2002). Molecular characterization of extended-spectrum β-lactamases produced by nosocomial isolates of Enterobacteriaceae from an Italian nationwide survey. Antimicrobial Agents and Chemotherapy 40, 611-14.
22. Winokur, P.I., Canton, P., Casellas, J. M. et al. (2001). Variations in the prevalence of srains expressing an extended spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas and the Western Pacific region. Clinical Infectious Diseases 32, Suppl. 2, S94-S103.
23. Thauvin-Eliopoulos, C., Tripodi, M. F., Moellering, R. C. et al. (1997). Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum β-lactamase-producing strain of Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy 41, 1053-7.
24. Lautenbach, E., Patel, J. B., Bilker, W. B. et al. (2001). Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clinical Infectious Diseases 32, 1162-71.
25. Paterson, D. L., Ko, W. C., Von Gottberg, A. et al. (2001). Outcome of cephalosporin treatment for serious infection due to apparently susceptible organisms producing extended-spectrum β-lactamase: implications for the clinical microbiology laboratory. Journal of Clinical Microbiology 39, 2206-12.
26. Rice, L. B., Yao, J. D., Klimm, K. et al. (1991). Efficacy of different β-lactams against an extended-spectrum β-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model. Antimicrobial Agents and Chemotherapy 35, 1243-4.
27. Rasheed, J. K., Jay, C., Methcock, B. et al. (1997). Evolution of extended-spectrum β-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episode of bacteremia. Antimicrobial Agents and Chemotherapy 41, 647-53.
28. Lin, M. F., Huang, M. L. & Lai, S. H. (2003). Risk factors in the acquisition of extended-spectrum β-lactamase Klebsiella pneumoniae: a case-control study in a district teaching hospital in Taiwan. Journal of Hospital Infection 53, 39-45.
29. Du, B., Long, Y., Liu, H. et al. (2002). Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Medicine 28, 1718-23.
30. Singh, N., Patel, K. M., Leger, M. M. et al. (2002). Risk of resistant infections with Enterobacteriaceae in hospitalized neonates. Pediatric Infectious Diseases Journal 21, 1029-33.
31. Kim, B. N., Woo, J. H., Kim, M. N. et al. (2002). Clinical implications of extended-spectrum β-lactamase-producing Klebsiella pneumoniae bacteraemia. Journal of Hospital Infection 52, 99-106.
32. Ho, P. L., Chan, W. M., Tsang, K. W. et al. (2002). Bacteremia caused by Escherichia coli producing extended-spectrum β-lactamase: a case-control study of risk factors and outcomes. Scandinavian Journal of Infectious Diseases 34, 567-73.
33. Kim, Y. K., Pai, H., Lee, H. J. et al. (2002). Bloodstream infections by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrobial Agents and Chemotherapy 46, 1481-91.
34. Einhorn, A. E., Neuhauser, M. M., Bearden, D. T. et al. (2002). Extended-spectrum β-lactamases: frequency, risk factors, and outcomes. Pharmacotherapy 22, 14-20.
35. Menashe, G., Borer, A., Yagupsky, P. et al. (2001). Clinical significance and impact on mortality of extended-spectrum β-lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia. Scandinavian Journal of Infectious Diseases 33, 188-93.
36. Lautenbach, E., Patel, J. B., Bilker, W. B. (2001). Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clinical Infectious Diseases 32, 1162-71.
37. Rebuck, J. A., Olsen, K. M., Fey, P. D. et al. (2000). Characterization of an outbreak due to extended-spectrum β-lactamase-producing Klebsiella pneumoniae in a pediatric intensive care unit transplant population. Clinical Infectious Diseases 31, 1368-72.
38. Pena, C., Pujol, M., Ricart, A. et al. (1997). Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum β-lactamase (ESBL-KP) in the intensive care unit. Journal of Hospital Infection 35, 9-16.
39. De Champs, C., Sauvant, M. P., Chanal, C. et al. (1989). Prospective survey of colonization and infection caused by expanded-spectrum-β-lactamase-producing members of the family Enterobactericaeae in an intensive care unit. Journal of Clinical Microbiology 27, 2887-90.
40. Bonfiglio, G., Perilli, M., Stefani, S. et al. (2002). Prevalence of extended spectrum β-lactamases among Enterobacteriaceae: an Italian survey. International Journal of Antimicrobial Agents 19, 213-7.